Background: PV is characterized by red blood cell overproduction. Rusfertide is a subcutaneous (SC), self-injected, first-in-class peptide hepcidin mimetic that decreases erythrocytosis. VERIFY ...

CD40 Ligand Blockade for Prevention of Graft-Versus-Host Disease This scoping review was conducted based on the Arksey and O'Malley framework and the work of Levac et al. The databases searched ...

Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m 2 [4g/m 2 once on day 1, then 2g/m 2 once on days 2-7] × six) to patients showing a ...

This study evaluated three LLMs (GPT-3.5-turbo-0125, GPT-4-turbo, and GPT-4o) using drug names from HemOnc ontology. The assessment included 367 generic-to-brand and 2,516 brand-to-generic pairs, ...

Individual patient data from 20 randomized multicenter trials were collected. Eleven studies (4,773 patients) with sufficient data were analyzed to evaluate whether 9- or 12-month MRD-CR classified at ...

Background: Although immunotherapy has changed the treatment strategy for many cancers with great success, patients with microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer (mCRC) ...

For the purpose of this paper, we define oncology rehabilitation as services provided by licensed medical providers (eg, physical or occupational therapists, physical medicine and rehabilitation ...

Background: CCTG PA.7 (NCT02879318) was a randomized phase II trial comparing gemcitabine (G) and nab-paclitaxel (N) with and without dual immune checkpoint inhibition with durvalumab (D) and ...

Pancreatic cancer is soon to be the second leading cause of cancer-related death in the United States. 1 Despite this reality, it is undeniable that there have been improvements in the management of ...

Risk of non-breast cancer–related mortality in breast cancer and dependence on disease characteristics, treatment, and survival duration. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Breast cancer is the most common cancer diagnosed in women, making it the second most commonly diagnosed cancer in the world. 1,2 About 2.3 million new breast cancer cases and 685,000 deaths occurred ...

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...